z-logo
open-access-imgOpen Access
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
Author(s) -
Jens Lundgren,
Birgit Grund,
Christina E. Barkauskas,
Thomas L Holland,
Robert Gottlieb,
Uriel Sandkovsky,
Samuel M. Brown,
Kirk U. Knowlton,
Wesley H. Self,
D. Clark Files,
Mamta K. Jain,
Thomas Benfield,
Michael E. Bowdish,
Bradley G. Leshnower,
Jason V. Baker,
JensUlrik Stæhr Jensen,
Edward M. Gardner,
Adit A. Ginde,
Estelle S. Harris,
Işık Somuncu Johansen,
Norman Markowitz,
Michael A. Matthay,
Lars Østergaard,
Christina C. Chang,
Victoria J. Davey,
Anna L. Goodman,
Elizabeth S. Higgs,
Daniel D. Murray,
Thomas A. Murray,
Roger Paredes,
Mahesh Parmar,
Andrew Phillips,
Cavan Reilly,
Shweta Sharma,
Robin Dewar,
Marc Teitelbaum,
Deborah Wentworth,
Huyen Cao,
Paul Klekotka,
Abdel G. Babiker,
Annetine C. Gelijns,
Virginia L. Kan,
Mark N. Polizzotto,
B. Taylor Thompson,
H. Clifford Lane,
James D. Neaton
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2033130
Subject(s) - covid-19 , virology , monoclonal antibody , medicine , antibody , neutralizing antibody , immunology , virus , outbreak , infectious disease (medical specialty) , disease
LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom